Covid emergency: the data on infections continue to fluctuate and the curve always records ups and downs, in the meantime the antibodies are studied to treat the variants of the virus. In fact Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline have announced a collaboration. A full synergy to evaluate the combination of two anti-Covid therapies with two different monoclonal antibodies. The study is ongoing in the Usa and Puerto Rico and has the purpose of stemming the spread of the variants of the virus.
Meanwhile, according to data released by the Ministry of Health, today they are registered 13.532 new positive cases (yesterday 13.908). The new deaths are 311 (yesterday 316). The discharged healed in the last 24 hours are 13.973 (yesterday 16.422); altogether the positive cases are 401.413, 761 cheaper than yesterday. The swabs made today are 290.534; the ICU patients are 2062. While in home isolation they remain 380.851 positive people at Covid.
Antibodies to the variants of the virus
The collaboration between Eli Lilly and Company, Vir Biotechnology and GlaxoSmithKline "is the first case in which monoclonal antibodies from different companies are paired to explore potential outcomes." This was announced by the pharmaceutical companies involved in the experimentation. The study evaluates the combination of bamlanivimab 700 mg with VIR-7831 500 mg: the hope is that this 'association of antibodies' will make it more difficult for the development of mutations.
In the world 108 million positive cases for Coronavirus
The cases of Coronavirus globally they have exceeded 108 million in the last few hours: this is what emerges from the data of Johns Hopkins University. According to the American university, the toll of infections in the world since the beginning of the pandemic is 108.186.991, included 2.382.880 deaths. So far, a total of 60.587.212 people have healed on all five continents.
